ArticleMedical & biological engineering & computing2026
Domain generalisation challenges in breast cancer molecular classification using foundation models: a cross-cohort exploratory study.
Article in Medical & biological engineering & computing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular classification guides breast cancer treatment, but PAM50 and immunohistochemistry (IHC) remain costly and unavailable in many settings. Foundation models (FMs) combined with multiple instance learning (MIL) show promise for predicting molecular subtypes from haematoxylin-and-eosin-stained slides, yet most studies report only internal validation. This study evaluates FMs with MIL across cohorts and identifies factors associated with domain-induced performance degradation. We evaluate 13 FMs and 3 complementary MIL architectures for PAM50 subtyping and IHC biomarker prediction using cross-validation on TCGA-BRCA ([Formula: see text]) and external validation on CPTAC-BRCA ([Formula: see text]). Virchow v2 achieves the best overall performance but exhibits severe degradation upon external validation, consistent across all three MIL architectures especially for HER2-enriched and Normal-like PAM50 subtypes and HER2-positive IHC prediction. Four hypothesised domain shift factors are quantified through exploratory regression analysis to explain relative performance drop (RPD). Staining variability, feature space divergence and morphological separability reach significance in univariate analysis, whilst prevalence shift does not. Staining variability and feature space divergence as covariate-level factors jointly account for 80.0% of RPD variance in the most parsimonious multivariate model ([Formula: see text], [Formula: see text]). Although based on a limited number of class-level observations and therefore exploratory in nature, these findings highlight the need for domain generalisation strategies targeting covariate shift, even when specialised FMs are used as feature encoders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.